Tag: NTDs

Pharma supports “Reaching a Billion – ending Neglected Tropical Diseases Gateway to UHC” report and call to action
10th annual G-FINDER report: Pharmaceutical industry R&D investment funding for neglected diseases continues to be a good news story
Progress report on biopharmaceutical industry contributions to the global fight against Neglected Tropical Diseases (NTDs)
Doing our part: Comprehensive efforts to fight Neglected Tropical Diseases (NTDs)
Doing our part: Innovating to fight Neglected Tropical Diseases
Zika Virus
2015 IFPMA pharma by numbers - Video
Neglected tropical diseases
R&D pipeline for malaria
Open letter to G7 Heads of State on neglected tropical diseases
Pharmaceutical industry makes progress in cutting-edge R&D for neglected diseases
Doing our part: Partnerships to boost R&D for unmet medical needs
Doing our part: landmark medicine donations
Doing our part: Comprehensive efforts to fight NTDs
Doing our part: Implementation of capacity-building efforts
WHO Executive Board 136 - Item 9.4, 2014 Ebola virus disease outbreak
Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions
Case study: Malaria
Case study: Dengue
World Health Day 2014: Protect yourself from vector-borne diseases
2013 Pharmaceutical R&D projects to develop new cures for patients with neglected conditions
Research-based pharmaceutical industry’s 360-degree efforts to fight neglected tropical diseases (NTDs)
Sustainable health and multi-stakeholder action: Lessons learned from the MDGs
Research-based pharmaceutical industry 360-degree efforts to fight Neglected Tropical Diseases (NTDs) 2013
WHA 66, Item 16.2, Neglected tropical diseases
2012 Pharmaceutical R&D projects to discover cures for patients with neglected conditions
WHO Executive Board, 132nd session IFPMA statement under agenda item 9.2
New report shows major increase in pharmaceutical research and development (R&D) for neglected diseases
A shared commitment to improving global health
Research-based pharmaceutical industry welcomes progress on key global health issues at World Health Assembly

Other Tags

Access Access to antiretrovirals Access to Medicines Access to vaccines Africa AMR AMR Industry Alliance Anti-Counterfeit Antibiotics antimicrobial resistance antivirals Assembly Biosimilars Biotherapeutic Medicines Biotherapeutics Cancer Code of Practice collaboration Counterfeit Medicines Counterfeits COVID-19 Dementia Developing World Economic footprint Efficacy Epidemics Ethics Ethics; Code; Business integrity; Compliance Event Highlights Fake Medicines Fakes Falsified Medicines Fight the Fakes Flu Global Health global health security harmonization Health Partnerships HIV/AIDS IFPMA IFPMA Statement Immunization Incremental Innovation Influenza Influenza Vaccination Infographic Infographics Innovation Innovation ecosystem Intellectual Property IP IVS Latin America Malaria MDGs Medicines Mental and Neurological Disorders NCDs Neglected Tropical Diseases News Releases Non-Communicable Diseases Novel Coronavirus (COVID-19) NTDs pandemic Pandemic Influenza Pandemic preparedness pandemics Partnerships Pharma Pharmacovigilance Position Paper Prevention Publications Public Health Quality R&D Regulatory regulatory systems Related Links Research Safety SDGs Seasonal Influenza Statements Supply chain Sustainable Development Goals Sustainable Innovation trade Treatments Tuberculosis UHC Universal Health Coverage Vaccine Vaccines Value of Innovation Videos WHA WHO WIPO Women’s Cancers